MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth

Christina Wilms1, Carsten M Kroeger1, Adelheid V Hainzl1

  • 1Department of Dermatology and Allergic Diseases, Ulm University, 89081 Ulm, Germany.

Oncotarget
|October 6, 2017
PubMed

Insights

The histone H2A deubiquitinase MYSM1 is upregulated in melanoma and drives tumor growth by epigenetically regulating genes like c-MET. Silencing MYSM1 reduces melanoma cell survival and proliferation, identifying it as a potential therapeutic target.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Molecular Oncology

Background:

  • Histone modifying enzymes, including histone deacetylases (HDACs) and polycomb repressive complex (PRC) components, are crucial in cancer development.
  • The histone H2A deubiquitinase 2A-DUB/Mysm1 (MYSM1) plays a role in hematopoiesis and tissue differentiation by influencing DNA-damage responses.
  • Alterations in MYSM1 have been observed in skin pigmentation and melanocyte specification, suggesting a potential role in melanoma.

Purpose of the Study:

  • To investigate the role of MYSM1 in melanoma formation and progression.
  • To determine if MYSM1 expression is altered in human melanoma samples and cell lines.
  • To evaluate the therapeutic potential of targeting MYSM1 in melanoma.

Main Methods:

  • Analysis of MYSM1 expression in human melanoma samples, nevi, and normal skin.
  • Detection of MYSM1 mRNA and protein levels in melanoma cell lines and murine skin.
  • Induction of MYSM1 expression by growth factors and UVB exposure.
  • Stable silencing of MYSM1 using lentivirally-mediated shRNA in melanoma cells.
  • Assessment of cell survival, proliferation, and soft agar colony formation in MYSM1-silenced cells.
  • Chromatin immunoprecipitation (ChIP) to identify MYSM1 binding sites, such as the c-MET promoter.

Main Results:

  • MYSM1 expression is significantly increased in human melanoma tissues compared to normal skin and nevi.
  • MYSM1 is expressed at mRNA and protein levels in melanoma cell lines and murine skin, inducible by growth factors and UVB.
  • Silencing MYSM1 in melanoma cells markedly reduces their survival and proliferation.
  • MYSM1-silenced cells exhibit reduced proliferation in soft agar assays.
  • MYSM1 was found to bind to the c-MET promoter region in melanoma cells.

Conclusions:

  • MYSM1 is an epigenetic regulator involved in melanoma cell growth and survival.
  • Increased MYSM1 expression is a feature of melanoma.
  • MYSM1 represents a promising novel therapeutic target for melanoma treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.0K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K